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Abstract
Background: Monoclonal gammopathy of undetermined significance (MGUS) is a common plasma cell
dyscrasia, comprising the most indolent form of monoclonal gammopathy. However, approximately 25%
of MGUS cases ultimately progress to plasma cell myeloma (PCM) or related diseases. It is difficult to
predict which subset of patients will transform. In this study, we examined the immunophenotypic
differences of plasma cells in MGUS and PCM.
Methods: Bone marrow specimens from 32 MGUS patients and 32 PCM patients were analyzed by 4-
color flow cytometry, using cluster analysis of ungated data, for the expression of several markers,
including CD10, CD19, CD20, CD38, CD45, CD56 and surface and intracellular immunoglobulin light
chains.
Results: All MGUS patients had two subpopulations of plasma cells, one with a "normal" phenotype
[CD19(+), CD56(-), CD38(bright +)] and one with an aberrant phenotype [either CD19(-)/CD56(+) or
CD19(-)/CD56(-)]. The normal subpopulation ranged from 4.4 to 86% (mean 27%) of total plasma cells.
Only 20 of 32 PCM cases showed an identifiable normal subpopulation at significantly lower frequency
[range 0–32%, mean 3.3%, p << 0.001]. The plasma cells in PCM were significantly less likely to express
CD19 [1/32 (3.1%) vs. 13/29 (45%), p << 0.001] and more likely to express surface immunoglobulin [21/
32 (66%) vs. 3/28 (11%), p << 0.001], compared to MGUS. Those expressing CD19 did so at a significantly
lower level than in MGUS, with no overlap in mean fluorescence intensities [174 ± 25 vs. 430 ± 34, p <<
0.001]. There were no significant differences in CD56 expression [23/32 (72%) vs. 18/29 (62%), p = 0.29],
CD45 expression [15/32 (47%) vs. 20/30 (67%), p = 0.10] or CD38 mean fluorescence intensities [6552 ±
451 vs. 6365 ± 420, p = 0.38]. Two of the six MGUS cases (33%) with >90% CD19(-) plasma cells showed
progression of disease, whereas none of the cases with >10% CD19(+) plasma cells evolved to PCM.
Conclusion: MGUS cases with potential for disease progression appeared to lack CD19 expression on
>90% of their plasma cells, displaying an immunophenotypic profile similar to PCM plasma cells. A higher
relative proportion of CD19(+) plasma cells in MGUS may be associated with a lower potential for disease
progression.
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Background
Plasma cell dyscrasias show a spectrum of clinical and
biological features, ranging from the more indolent
forms, such as monoclonal gammopathy of undeter-
mined significance (MGUS) to more aggressive entities
viz. plasma cell myeloma (PCM) and plasma cell leuke-
mia. MGUS is the most common, predominantly benign
plasma cell disorder and yet a significant number of cases
will eventually progress to PCM or related diseases. The
overall incidence of progression to myeloma is estimated
to be approximately 1% per year [1,2]. However, even
with the recent advances in our understanding of the
pathogenesis and risk factors in MGUS, it is difficult to
predict accurately which subset of patients will transform.
It is important to make this distinction because the early
identification of patients in the high-risk group would
allow the development of effective chemotherapeutic
strategies. In general, the majority of MGUS patients have
a protracted disease course and die of an unrelated condi-
tion, but the potential for progression has been demon-
strated even after decades. Thus, chemopreventive
regimens would be appropriate in the correct setting [3,4].
A combination of clinical and laboratory parameters is
used in distinguishing MGUS form PCM. According to the
World Health Organization criteria [5], MGUS is defined
by a monoclonal serum protein at less than myeloma lev-
els; fewer than 10% bone marrow plasma cells; the
absence of lytic lesions and the lack of myeloma-related
organ or tissue impairment. Several biological criteria
have been proposed as predictors of the transition of
MGUS to PCM or related malignancies, many of them
related to the differential expression of plasma cell pro-
teins or molecules that mediate the interaction of plasma
cells with the bone marrow environment [6-9]. Flow
cytometry is a sensitive and comprehensive technique that
has been successfully employed in the diagnosis and fol-
low-up of plasma cell dyscrasias [10-12]. Although immu-
nophenotypic studies have been previously performed in
MGUS and PCM patients, primarily for the differential
diagnosis of borderline cases, there is relatively little infor-
mation on the role of routine flow cytometry in identify-
ing MGUS patients with potential for disease progression.
In this study, we examined the immunophenotypic differ-
ences in plasma cells in MGUS and PCM and evaluated
their utility in predicting disease progression.
Methods
The University of Texas Southwestern Medical Center
Flow Cytometry Laboratory database was searched over a
period of ten years for cases with aberrant plasma cell
clones, consistent with a plasma cell dyscrasia. Thirty-two
patients each were identified as fulfilling the clinical and
pathologic criteria for MGUS and PCM, respectively,
according to the World Health Organization published
guidelines. Their clinical data were obtained through
review of medical records. The study was conducted in
accordance with the Helsinki Declaration, as approved by
the UT Southwestern Institutional Review Board (Proto-
col # 052008-074).
All patients had a bone marrow sample obtained at the
time of the initial presentation immunophenotyped with
a "myeloma panel", consisting of antibodies against CD4,
CD5, CD8, CD10, CD11b, CD14, CD16, CD19, CD20,
CD34, CD38, CD45, CD56, and monoclonal and poly-
clonal reagents against surface and intracellular kappa and
lambda light chains. The following antibody combina-
tions were used (listed in the FITC/PE/PerCP/APC fluoro-
chrome conjugate sequence): CD10/CD19/CD20/CD38,
CD14/CD56/CD45/CD38, monoclonal kappa/mono-
clonal lambda/CD19/CD38, CD5/CD4/CD8/CD19,
CD16/CD11b/CD45/CD34, intracellular monoclonal
kappa/intracellular monoclonal lambda/CD45/CD38,
intracellular polyclonal lambda/intracellular polyclonal
kappa/CD45/CD38. None of the patients was receiving
therapy related to their condition at the time of the bone
marrow biopsy.
For preparation of single cell suspensions for 4-color flow
cytometry, bone marrow specimens were incubated for 10
minutes with a standard ammonium chloride lysing solu-
tion (1 part sample to 9 parts lysing solution). The sam-
ples were then washed twice with phosphate-albumin
buffer (PAB), 0.05% sodium azide, and 0.1% bovine
serum albumin solution (BSA) and resuspended in RPMI
1640 culture medium supplemented with 5% fetal calf
serum. An aliquot of 5 × 105 cells was stained with a com-
bination of 4 antibodies conjugated with fluorescein iso-
thiocyanate (FITC), phycoerythrin (PE), peridinin
chlorophyll protein (PCP), or allophycocyanin (APC) at
2–8°C in the dark for 20 minutes. For the detection of
intracellular markers, a permeabilization step was per-
formed prior to the staining procedure. The amount of
antibody added was based on the manufacturer's recom-
mendations. At least 30,000 events were acquired rou-
tinely using a FACSCalibur flow cytometer with CellQuest
software (Becton Dickinson, San Jose, CA). Data analysis
was performed using Paint-A-Gate software (Becton Dick-
inson).
The following antibodies were obtained from Becton
Dickinson, unless otherwise specified: CD4 (SK3), CD
5(L17F12), CD8 (SK1), CD10 (W8E7), CD11b (D12),
CD14 (MP9), CD16 (NKP15), CD19 (SJ25C1), CD20
(L27), CD38 (HB7), CD45 (2D1), CD56 (MY31), poly-
clonal kappa and polyclonal lambda (goat IgG; Beckman
Coulter, Miami, FL). In general, distinct cell populations
were identified using CD45/forward and orthogonal lightBMC Clinical Pathology 2008, 8:13 http://www.biomedcentral.com/1472-6890/8/13
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scatter characteristics, in combination with various anti-
bodies. An antigen was considered positive if >20% of a
population cluster expressed the antigen based on a 2%
isotypic control threshold.
Statistical analyses of data were carried out in Origin
(OriginLab, Northampton, MA) and Excel (Microsoft,
Redmond, WA); a p-value < 0.05 was considered statisti-
cally significant.
Results
Clinical and laboratory characteristics
The MGUS cohort consisted of 16 men and 16 women
with a mean age of 59 years (range, 38 to 77 years). The
mean age of PCM patients (21 males and 11 females) was
62 years (range, 39 to 84 years). Median follow-up was 80
months for the MGUS group and 36 months for the PCM
cohort. Statistically significant differences between the
MGUS and PCM group were observed in the hemoglobin
concentration, amount of monoclonal component, lac-
tate dehydrogenase, presence of osteolytic bone lesions,
number of reduced immunoglobulin classes, and percent-
age of bone marrow plasma cells estimated by morpho-
logic examination and flow cytometry. In contrast, total
serum protein, calcium, and β2-microglobulin did not
show significant differences. The patients' pertinent
demographic and laboratory data are summarized in
Table 1.
FC analysis of plasma cells
Neoplastic plasma cells were defined by bright expression
of CD38 and restricted intracellular and/or surface immu-
noglobulin light chain expression. In order to distinguish
normal from aberrant plasma cells, we analyzed the
expression of CD19 and CD56 surface antigens. Plasma
cells of normal individuals typically express CD19, are
negative for CD56 [CD19(+)/CD56(-)] and are polyclo-
nal. Monoclonal plasma cells are either CD19(-)/
CD56(+) or CD19(-)/CD56(-) and thus phenotypically
aberrant. Figure 1 demonstrates the immunophenotype
of a typical case of PCM and Figure 2 illustrates a typical
case of MGUS. Of note, neoplastic plasma cells are slightly
dimmer for CD38 as compared to residual polytypic
plasma cells (Figure 2).
All 32 MGUS patients (100%) showed two immunophe-
notypically different plasma cell populations, one with a
normal and the other with an aberrant phenotype (Figure
3). The normal subpopulation accounted for 4.4–86%
(mean 27%) of all bone marrow plasma cells (Figure 4).
In contrast, only 20 of 32 PCM cases (62.5%, p < 0.001)
showed a phenotypically normal population, ranging
from 0–32% (mean 3.3%); this population was signifi-
cantly smaller than in the MGUS group (Figure 4). This
finding reflects the most striking difference between the
two patient cohorts, which was CD19 expression of total
plasma cells.
Total plasma cells in MGUS were more likely to express
CD19 (13/29 cases, 45%) than those in PCM (1/32 cases,
3.1%, p < 0.001). However, the opposite was true for sur-
face immunoglobulin light chain expression, were the
majority of PCM cases had surface immunoglobulins (21/
32, 66%) as compared to MGUS (3/28, 11%, p < 0.001).
The frequency of CD56(+) total plasma cells was similar
in MGUS (23/32, 72%) and PCM (18/29, 62%, p = 0.29).
There were also no significant differences in CD45 expres-
sion (20/30, 67% in MGUS vs. 15/32, 47% in PCM, p =
0.1). A comparison of antigen expression in plasma cells
of MGUS vs. PCM is summarized in Figure 4.
The expression of CD19 in MGUS plasma cells was signif-
icantly brighter than in PCM: the average ± standard devi-
ation (SD) mean fluorescence intensity (MFI) of CD19 in
MGUS was 430 ± 34, whereas the average ± SD MFI in
PCM 174 ± 25 (p << 0.001). Although PCM plasma cells
expressed CD38 at a dimmer level as compared to MGUS,
there was no statistically significant difference in CD38
Table 1: Demographic and laboratory characteristics in patients with MGUS and PCM.
Parameter MGUS (n = 32) PCM (n = 32) P value Reference range
Age 59 ± 12 62 ± 12 0.17 -
M:F 1:1 1.9:1 - -
Hemoglobin, g/L 121 ± 16 99 ± 21 <0.005 121 – 161
Total protein, g/L 75 ± 13 73 ± 19 0.29 63 – 82
M component, g/L 10 ± 9 38 ± 20 <0.005 -
Calcium, g/L 0.089 ± 0.009 0.09 ± 0.011 0.28 0.084–0.102
β2-microglobulin, mg/L 2.4 ± 1.3 4.9 ± 3.6 0.02 0.7–1.8
Lactate dehydrogenase, U/L 184 ± 50 271 ± 99 <0.005 100 – 190
Osteolytic bone lesions 0% 100% <0.005 -
Number of reduced Ig classes 0.2 ± 0.6 1.9 ± 0.4 <0.005 -
% plasma cells by morphology 4.2 ± 2.3 41 ± 21 <0.005 -
% plasma cells by flow cytometry 0.7 ± 0.8 19 ± 16 <0.005 -BMC Clinical Pathology 2008, 8:13 http://www.biomedcentral.com/1472-6890/8/13
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MFI (7020 ± 451 in MGUS vs. 6365 ± 420 in PCM, p =
0.130).
MGUS patients with progression of disease
Two out of 6 (2/6, 33%) MGUS cases with >90% CD19(-
) plasma cells showed progression of disease, whereas
none of the 26 (0/26, 0%) cases with <10% CD19(-)
plasma cells evolved to PCM. Progression was established
according to the criteria defined by the International Mye-
loma Working Group [13]. Table 2 summarizes labora-
tory data of the two MGUS patients with progression of
disease. With the exception of the percentage of bone mar-
row plasma cells and the amount of the urinary mono-
clonal protein, which are presented as a range from
diagnosis to the latest follow-up, the rest of the laboratory
data are from the latest follow-up. Both patients had an
increase in the percentage of bone marrow plasma cells
and Bence-Jones proteinuria within a similar interval
(time from diagnosis to progression = 48 months, each).
As a group, the MGUS patients had an estimated progres-
sion-free survival (PFS) of 67% at 5 years, while the cases
with <10% CD19(-) plasma cells had an estimated PFS of
100% at 5 years. At the time of completion of this study,
the two MGUS patients which showed related organ or tis-
sue impairment (ROTI), specifically renal insufficiency,
had not received myeloma-directed chemotherapy, but
were followed and treated for their renal impairment.
Discussion
The distinction between MGUS and PCM is an important
one for diagnostic, therapeutic, and prognostic purposes.
Furthermore, the ability to identify MGUS patients with
potential of progression of disease can offer to this group
of patients early treatment options without increasing the
morbidity of what is otherwise a relatively indolent entity.
Flow cytometry has been proven as an effective tool in dis-
tinguishing normal plasma cells from their neoplastic
counterparts by using both three-color [10,14,15] and
four-color staining [11]. This method is useful not only in
separating MGUS from PCM cases [10,14,15], but also in
evaluating minimal residual disease and offering predic-
tive information on therapeutic outcomes [12,16,17].
Flow cytometric analysis of plasma cell myeloma Figure 1
Flow cytometric analysis of plasma cell myeloma. Mature B lymphocytes are painted in blue and neoplastic plasma cells 
in red.BMC Clinical Pathology 2008, 8:13 http://www.biomedcentral.com/1472-6890/8/13
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We undertook the present study to evaluate the efficacy of
our flow cytometry antibody cocktails in detecting plasma
cells in MGUS and PCM. Based on the immunopheno-
typic profiles obtained from this analysis, we then
extended our study to investigate the clinical utility of
some routinely used surface and intracellular markers in
predicting MGUS cases at risk for progression. Our study
demonstrates that bone marrow specimens from all
MGUS cases had two distinct subpopulations of plasma
cells, according to their expression of CD19 and CD56.
One of these populations is found in all cases of MGUS
and is considered phenotypically normal and polyclonal,
while the second one is monoclonal and phenotypically
aberrant. In contrast, PCM patients had a normal subpop-
ulation in only less than two thirds of the cases, and these
plasma cells accounted for an average of less than 4% of
the total bone marrow plasma cells. The findings are sim-
ilar to those reported in previous studies that employed
three-color techniques [10,14,15]. The percentage of
residual normal plasma cells is thus an effective parameter
in the differential diagnosis of PCM vs. MGUS.
There are numerous studies that have examined the
immunophenotypic characteristics of plasma cells in
PCM [18,19] and/or MGUS [10,14,15,20,21]. Some of
these authors have used CD138 as a selective marker for
separating immunophenotypically normal from neoplas-
tic plasma cells, and a recent report of the European Mye-
loma Network has demonstrated that a combination of
CD138, CD38 and CD45 antibodies allows the most
reproducible detection of neoplastic plasma cells [22].
Others have employed a CD38/CD45/CD19/CD56 anti-
body cocktail tube to distinguish neoplastic plasma cells
from their normal counterpart [11]. By selecting plasma
cells using a similar approach and in combination with
light chain restriction (5 ≤ κ/λ ratio ≤ 0.5), we felt we can
discriminate between monoclonal and polyclonal plasma
cells present in the same specimen and separate them
from other hematopoietic cells, in particular hema-
togones. Furthermore, the frequency of CD19 and CD56
expression in PCM plasma cells detected in the present
study is similar to the range reported in the literature,
namely, <1–10% and 71–79%, respectively. Interestingly,
Immunophenotypic analysis of monoclonal gammopathy of undetermined significance Figure 2
Immunophenotypic analysis of monoclonal gammopathy of undetermined significance. Highlighted in red are neo-
plastic plasma cells; mature B lymphocytes are painted in blue and polytypic plasma cells in green.BMC Clinical Pathology 2008, 8:13 http://www.biomedcentral.com/1472-6890/8/13
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the present study found a higher frequency of CD45
expression than in the large series reported by Lin and col-
leagues (45% in our cases vs. 9% reported by Lin et
al.)[19]. However, this value is similar to that reported in
a series of previously characterized PCM cases in our lab-
oratory [23]. A range of CD45 expression has been dem-
onstrated in other studies [24,25] and may be due to
genetic and biologic heterogeneity of neoplastic cells in
each study [25,26].
In the present study, the number of MGUS patients lack-
ing CD19 expression in >90% of their total bone marrow
plasma cells was significantly lower than in the PCM
group. One third of MGUS patients with a predominance
of CD19(-) plasma cells had evidence of progression of
disease, whereas none of those with <10% of CD19(-)
total plasma cells did. This indicates that the ratio of
immunophenotypically abnormal to total bone marrow
plasma cells is helpful not only in providing a flow cyto-
metric separation of PCM from MGUS, but may also have
predictive information when evaluating MGUS patients
with potential for disease progression. While somewhat
limited by the length of follow-up and the number of
cases analyzed, our findings are consistent with the results
of a recent study, which evaluated a large cohort of MGUS
and smoldering myeloma patients and found that 24% of
MGUS patients with >95% aberrant plasma cells of total
bone marrow plasma cells progressed to PCM, as com-
pared to only 4% of cases with <95% of aberrant plasma
cells [27]. Of note, our cut-off used for defining MGUS
with potential for disease progression (<10%) was not
identical to the one in the afore-mentioned study (<5%)
which may pose an issue in terms of reaching a consensus
and would be also important in the setting of minimal
residual disease monitoring. Apart from the latter study,
there are few reports in the literature addressing the utility
of flow cytometric markers used in the routine practice
that arrived to a similar conclusion [28]. In contrast, there
is extensive information on the immunophenotypic pro-
file of plasma cells associated with an active of aggressive
Comparison of CD19 and CD56 expression in plasma cells of monoclonal gammopathy of undetermined significance (MGUS) Figure 3
Comparison of CD19 and CD56 expression in plasma cells of monoclonal gammopathy of undetermined signif-
icance (MGUS). The top row shows CD19 expression in polytypic (yellow) and neoplastic (red) plasma cells in three different 
MGUS cases. The corresponding CD56 expression is demonstrated in the bottom row.BMC Clinical Pathology 2008, 8:13 http://www.biomedcentral.com/1472-6890/8/13
Page 7 of 9
(page number not for citation purposes)
Comparison of normal plasma cell population size in monoclonal gammopathy of undetermined significance (MGUS) and  plasma cell myeloma (PCM) Figure 4
Comparison of normal plasma cell population size in monoclonal gammopathy of undetermined significance 
(MGUS) and plasma cell myeloma (PCM). MGUS cases (red) have a significantly higher CD19(+) plasma cell population 
as compared to PCM cases (green). There are no significant differences in CD56 and CD45 expression. Horizontal bars repre-
sent mean values.
Table 2: Laboratory characteristics of MGUS patients with progression of disease.
Parameter MGUS #1 MGUS #2 Reference range
Hemoglobin, g/L 133 140 121 – 161
Total protein, g/L 74 45 63 – 82
Creatinine, g/L 0.019 0.046 0.006–0.012
Calcium, g/L 0.089 0.091 0.084–0.102
β2-microglobulin, mg/L 4.9 12.1 0.7–1.8
LDH, U/L 204 223 140–271
% PC by morphology 4.6 ⇒ 10 8.5 ⇒ 12 -
Urinary M component (mg/24 hrs) 647 ⇒ 1,640 755 ⇒ 1,786 -
κ:λ light chain ratio 79.4 44.8 0.26–1.65BMC Clinical Pathology 2008, 8:13 http://www.biomedcentral.com/1472-6890/8/13
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disease course. Some of these markers, such as CD86,
CD126, CD130, HLA-1, β2-microglobulin, MPC-1,
CD49e, CD200 [7-9] may be less seldom employed in
routine flow cytometry panels. Other studies used micro-
arrays to evaluate global gene expression for determining
the molecular fingerprint associated with malignancy
[6,29-32]. These authors were able to identify genes that
are involved in the sequential transformation of normal
to malignant plasma cells and thus can be useful in iden-
tifying the progression of MGUS to PCM.
These and other reports underscore the existence of a bio-
logical continuum from normal plasma cells, to MGUS,
and to PCM or other related malignancies. MGUS patients
are largely asymptomatic and are progressing over time to
more aggressive disease at a relatively low rate (1% per
year), which does not diminish over time [1,2]. Genetic
instability and bone marrow microenvironmental
changes are some of the factors that have been postulated
to play a role in progression. For prognostic purposes, a
risk-stratification system has been proposed, based on
three risk factors: amount of the serum monoclonal com-
ponent, immunoglobulin type and serum free light chain
ratio [33]. In addition, percentage of aberrant bone mar-
row plasma cells and DNA aneuploidy were strong predic-
tors for progression-free survival in another recent study
[27].
Conclusion
In summary, we evaluated the usefulness of various rou-
tine immunophenotypic markers in characterizing cases
of MGUS and in a small series, identified patients lacking
CD19 on the majority of their bone marrow plasma cells
as being more likely to show progression of disease. Based
on similar findings reported in a comprehensive study
[27], it appears that flow cytometric evaluation of CD19
expression in bone marrow plasma cells could be incor-
porated as an adjunctive test in the current patient stratifi-
cation schemes.
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